Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 1053-8569, Iss. 10, 2015-10 ,pp. : 1058-1067

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relationship between Reductions in Parathyroid Hormone and Serum Phosphorus during the Management of Secondary Hyperparathyroidism with Calcimimetics in Hemodialysis Patients

By  

Nephron Clin Pract, Vol. 121, Iss. 3-4, 2012-11 ,pp. : c124-c130

Karger

Access to resources Recommend Favorite

Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients

By Sharma Amit   Ketteler Markus   Marshall Thomas S.   Khan Samina S.   Schumock Glen T.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1129-1136

Informa Healthcare

Access to resources Recommend Favorite

By  

THERAPEUTIC APHERESIS AND DIALYSIS, Vol. 19, Iss. 4, 2015-08 ,pp. : 367-377

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 91-2700, Iss. 11, 2015-11 ,pp. : 1280-1285

John Wiley & Sons Inc

Access to resources Recommend Favorite